Clinical and Biological Responses to Repeated Administration of Low-dose Interleukin-2 in Patients With Type 1 Diabetes and a Residual Insulin Secretion
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Aldesleukin (Primary) ; Ciclosporin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DFIL2-REP
- 21 Nov 2024 Planned End Date changed from 21 Jul 2026 to 21 Apr 2026.
- 21 Nov 2024 Planned primary completion date changed from 21 Oct 2024 to 21 Apr 2026.
- 11 Aug 2023 Planned End Date changed from 1 Jul 2025 to 21 Jul 2026.